The latest research waiting for you

Here you find Research our Clients trust us with allocating to the best research sites globally.
To participate, please request password at hi@yendou.io

Breast Cancer

ER+/HER2-

Phase II

Interventional

Multinational

AMRA-BREAST-01:

A Randomised, Multicentre, Double-Blind, Phase II Clinical Trial Evaluating the Safety and Efficacy of Oral Selective Estrogen Receptor Degrader (SERD) in Metastatic Breast Cancer Patients with ER+ and HER2- Status, Who Have Not Received Prior Systemic Treatment for Advanced Disease

Hematology

Phase I

Interventional

Multinational

YND-H-01 in Hematologic Malignancies

This is a Phase 1 dose-escalation study of a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of specific CDK9 Inh.